Company Overview of Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as...
Hi-Tech Park 2/4
PO Box 39098
Founded in 2002
Key Executives for Oramed Pharmaceuticals Inc.
Chief Executive Officer
Total Annual Compensation: $259.7K
Chief Financial Officer
Total Annual Compensation: $98.4K
Chief Operating Officer and Vice President of Business Development
Total Annual Compensation: $48.4K
Chief Medical & Technology Officer and Director
Total Annual Compensation: $188.4K
Compensation as of Fiscal Year 2013.
Oramed Pharmaceuticals Inc. Key Developments
Oramed Pharmaceuticals Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 10:00 AM
Sep 3 14
Oramed Pharmaceuticals Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 10:00 AM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.
Oramed Pharmaceuticals Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM
Aug 30 14
Oramed Pharmaceuticals Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.
Oramed Pharmaceuticals Inc. Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
Aug 7 14
Oramed Pharmaceuticals Inc. reported that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study in patients with established type 1 diabetes is evaluating the safety and impact of ORMD-0801 on the exogenous insulin requirements in 24 type 1 diabetics patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|